本文選題：非霍奇金淋巴瘤　切入點：免疫球蛋白重鏈　出處：《第一軍醫(yī)大學(xué)》2006年碩士論文　論文類型：學(xué)位論文

【摘要】：一、研究背景和目的 淋巴瘤病理診斷是臨床病理診斷的難題之一，2001年世界衛(wèi)生組織(WHO)定義惡性淋巴瘤中每一個獨立疾病(或類型)需要結(jié)合形態(tài)學(xué)、免疫表型、遺傳學(xué)和臨床特點來確定，特別強(qiáng)調(diào)基因重排檢測技術(shù)輔助診斷淋巴瘤的重要性。大部分可疑的高度反應(yīng)增生性淋巴組織，可以通過組織形態(tài)學(xué)和細(xì)胞形態(tài)學(xué)結(jié)合免疫組化或流式細(xì)胞技術(shù)檢測免疫表型來與惡性淋巴瘤甄別。但還有大約5～15％的病例難以確診。原則上，惡性淋巴瘤的瘤細(xì)胞都來自一個共同的克隆，所以能夠依靠克隆性鑒定來進(jìn)行輔助診斷。 淋巴細(xì)胞惡性腫瘤以B細(xì)胞來源為主，約占90％，免疫球蛋白重鏈基因(IgH)分析方法主要有DNA印跡法(Southern blot)、PCR、測序等。以PCR技術(shù)為基礎(chǔ)的方法以其簡便、高效、廉價及適用面廣而在淋巴瘤基因重排研究方面越來越受重視。但不同研究文獻(xiàn)中所采用的引物、PCR條件、PCR產(chǎn)物檢測方法等都不盡相同，結(jié)果也有差異。難以找到適于常規(guī)臨床病理診斷的標(biāo)準(zhǔn)程序，影響了PCR技術(shù)的應(yīng)用價值。 2003年歐洲七國47個研究所的病理學(xué)家、分子生物學(xué)家及其它研究人員經(jīng)過四年半的研究發(fā)表了標(biāo)準(zhǔn)化引物系統(tǒng)(BIOMED-2)，建立了用于克隆性分析的基因重排及染色體易位檢測的PCR方法學(xué)和引物設(shè)計的標(biāo)準(zhǔn)化，可檢測出幾乎所有克隆性T、B細(xì)胞克隆細(xì)胞群乃至高度體細(xì)胞突變B細(xì)胞淋巴瘤／白血病，實現(xiàn)了前所未有高檢出率。BIOMED-2引物系統(tǒng)是劃時代的，其設(shè)計思想十分先進(jìn)，，將該技術(shù)進(jìn)一步完善并及早運用于臨床已勢在必行，但該系統(tǒng)過于龐大復(fù)雜，目前在國內(nèi)難以推廣應(yīng)用，更不利于臨床診斷的使用。本研究以淋巴瘤
[Abstract]:I. background and purpose of the study. The pathological diagnosis of lymphoma is one of the difficult problems in clinicopathological diagnosis. In 2001, the World Health Organization (WHO) defined each individual disease (or type) in malignant lymphoma to be determined by combining morphology, immunophenotype, genetics and clinical characteristics. Emphasizing in particular the importance of gene rearrangement techniques to assist in the diagnosis of lymphoma. Most suspicious highly reactive proliferative lymphoid tissues, Histomorphology and cell morphology combined with immunohistochemistry or flow cytometry can be used to detect the immunophenotype of malignant lymphoma. But there are still about 55% of the cases that are difficult to diagnose. In principle, Malignant lymphoma cells are derived from a common clone, so can rely on clonal identification to assist the diagnosis. The immunoglobulin heavy chain gene (Ig) analysis method mainly includes DNA blotDNA, sequencing and so on. The method based on PCR technique is simple and efficient. More and more attention has been paid to the gene rearrangement of lymphoma due to its low cost and wide application. It is difficult to find a standard procedure suitable for routine clinicopathologic diagnosis, which affects the application value of PCR technique. In 2003, pathologists at 47 institutes in seven European countries, After four and a half years of research, molecular biologists and other researchers have published a standardized primer system, BIOMED-2, and established PCR methodology and standardization of primer design for gene rearrangement and chromosome translocation detection for clonal analysis. It can detect almost all clone T B cell colony and even high somatic mutation B cell lymphoma / leukemia. It is epochal to realize the unprecedented high detection rate of BIOMED-2 primer system, and its design idea is very advanced. It is imperative to improve the technique and apply it to clinical practice as soon as possible, but the system is too large and complex, so it is difficult to be popularized and applied in China at present, which is even more unfavorable for clinical diagnosis.
【學(xué)位授予單位】：第一軍醫(yī)大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2006
【分類號】：R392

【參考文獻(xiàn)】

相關(guān)期刊論文 前9條

1 邢佩霓,王彤,李梅生,呂曉莉;多聚酶鏈反應(yīng)結(jié)合酶切與異源雙鏈形成分析檢測白血病微小殘留病[J];白血病;1998年02期

2 王小寧;受體編輯/修正——免疫識別與耐受的新模式[J];第二軍醫(yī)大學(xué)學(xué)報;2002年10期

3 朱梅剛,張素娟,李春富,趙彤,高云飛;NHL患者外周血淋巴細(xì)胞基因重排檢測及意義[J];第一軍醫(yī)大學(xué)學(xué)報;1998年01期

4 寧佩芳;血清DNA檢測與腫瘤診斷[J];國外醫(yī)學(xué)(臨床生物化學(xué)與檢驗學(xué)分冊);2002年04期

5 傅士龍,劉嘉茵;腫瘤循環(huán)DNA的研究進(jìn)展[J];臨床腫瘤學(xué)雜志;2005年01期

6 姜華,傅衛(wèi)軍,丁思奇,侯健;血液系統(tǒng)腫瘤患者外周血細(xì)胞IgH基因和TCRγ基因的檢測及意義[J];上海免疫學(xué)雜志;2000年02期

7 應(yīng)韶旭,林果為,梁曉華,周鑫莉,浦權(quán),楊梅如;單克隆IgH基因重排檢測在B-NHL診斷和隨訪中的意義[J];上海醫(yī)學(xué);2002年03期

8 張建中;第24屆國際病理學(xué)大會簡介[J];中華病理學(xué)雜志;2003年01期

9 馮琦,李紅玲,孫凱,蘇明權(quán),尚振川,孫秉中;血清及血漿標(biāo)本IgH基因重排對B細(xì)胞淋巴瘤患者的診斷價值[J];中華內(nèi)科雜志;2005年06期

本文編號：1564998